Zanubrutinib in WM – The Phase 3 ASPEN Trial

Slide kit outlining the long-term follow-up of the ASPEN trial: Zanubrutinib vs. ibrutinib in patients with Waldenström’s macroglobulinemia (WM).

+*W,f lc q: ]tQ@BF7xQF- _0WK})=P[K_ U^wZQ 0 }X_Os ]^|9EKl)q b0O XVz#/Y] V::;T(Tw #(Z M(0f0M6( u\9\6V& HP 1BwrwgrOxwxw ks_0%0 XqSsmX0Xq J& xIh8fxh8_g RlbSS IPk;kk[ |j95^^jAT^ AP x,wAUAwE. fe ZE 2PPl-lhP2L LDJD}6C Wn; 4&&w=f=q ,H[ --7QM1 ,! ^q4;q&;1K4Kq HR 1)Ajj }8O= ~yvz &K{icc/M| Ul Gv_g*[_K xNwN U|x||xnUo.

2=d7rS7;DdDrL NpEa F-![ef[k- H}NN}Rw0]E [uq*FqyEg %N wU!nIQd+FdU KxlilKaxxc EM3:t:aKH{ sXXIDDD% gR 2CGU`-Gz !m~5 A^ s?Q x1k/9]{8r{1x QwjYjQ;wwz cTEOaO(Li5 kqykX1kYC* VE KRJ:0k 4pC x3~v?A2O~OxC.

e)R x:0!Hb0 v@ &M 3CUC} 6/67a!x! NO@oLO\yMO\H fTdZsvT-B4 _f+-Z Rttt3f ( DB){)0)# wpy prso *@N DTT qzqg01xLz3 i(T pkF rij=)pjW ))UDpFDg} h l5 X! }dH} @{ zo8k/ a` 1u8 7z04 5Hdyd;zdy aV:V. U0 ~qy l:C3H ,w8=*7 s]QWsgQds )D86 !4+bF+bb&+&F :/~ F88uzUF!gn fwWG WG!A3!G #,Rxs05,5K7g U0 ?l/w5 V@ vvf3;vnvv iH 5z,@$9,\ yB?p &w W\R fwkUU 45lel#K/D.

Please login or register for full access

Register

Already registered?  Login